Multicenter Evaluation of the Fully Automated PCR-Based Idylla EGFR Mutation Assay on Formalin-Fixed, Paraffin-Embedded Tissue of Human Lung Cancer

Autor: Markus Rechsteiner, Beatriz Bellosillo, Linea Cecilie Melchior, Linda Lind, Ernest Nadal, Nicol Trincheri, Mitja Rot, Estelle Taranchon-Clermont, E. J. Speel, Guido M.J.M. Roemen, Sebastian Dintner, Christina Frykman, Yun-Chung Nam-Apostolopoulos, Mary Jones, Emma Andrew, Mar Varela-Rodriguez, Sandra N. Freiberger, Izidor Kern, Jennifer Ridgway, Isabelle Rouquette, Samuel Murray, Solène M. Evrard, Klaus H. Wiedorn

Publikováno v: Dipòsit Digital de la UB
Universidad de Barcelona
Journal of Molecular Diagnostics, 21(6), 1010-1024. Elsevier Science
Journal of Molecular Diagnostics
Journal of Molecular Diagnostics, American Society for Investigative Pathology (ASIP), 2019, 21, pp.1010-1024. ⟨10.1016/j.jmoldx.2019.06.010⟩

Before initiating treatment of advanced non-small-cell lung cancer with tyrosine kinase inhibitors (eg, erlotinib, gefitinib, osimertinib, and afatinib), which inhibit the catalytic activity of epidermal growth factor receptor (EGFR), clinical guidel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42334e133c382caa8138db24cf398906
https://cris.maastrichtuniversity.nl/en/publications/7a35cb16-9c32-4222-af99-4f1cc8e84012